Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Interest in bicyclic amines kicked up early in the 20th century as researchers started mapping what rigid, nitrogen-bearing frameworks could do for drug design. As medicinal chemistry gained its footing after World War II, the search for structurally unique scaffolds led scientists to compounds like 6,6-Dimethyl-3-Azabicyclo[3.1.0]Hexane. Early synthesis efforts rooted this molecule in the broader study of tropane and homotropane pharmacophores, eventually catching the attention of pharmacologists who noticed its ring tension offered special interactions with biological targets. The story here ties tightly with the evolution of custom-designed APIs for CNS, pain management, and addiction science, especially as regulatory bodies standardized monographs through BP, EP, and USP, nudging producers toward tighter controls and documentation for every lot that left a plant.
Looking at 6,6-Dimethyl-3-Azabicyclo[3.1.0]Hexane in pharma grade, you don’t find something relegated to a shelf. This compound provides a fine entry for synthetic chemists chasing new CNS agents, enzyme inhibitors, and diagnostic markers. Suppliers connected to GMP-certified labs ship this in tightly sealed drums or amber glass under nitrogen, reflecting just how sensitive the material can be to moisture and air. Certification under BP, EP, and USP benchmarks tells buyers everything about trace impurities—especially heavy metals, solvents, and residual nitrogenous contaminants—not to mention detailed records about the starting batch, synthesis history, and result consistency per analytical batch.
This molecule feels compact and almost stubbornly rigid. Its bicyclic nature brings robust heat and chemical stability, with a melting point hovering close to room temperature but rising as impurity loads drop. It carries a mild amine odor—not sharp, but distinct enough that nobody mistakes it for anything else in the lab. Water solubility comes in lower than basic amines; organic solvents pick it up more willingly. Proton magnetic resonance spectra display the story of ring strain and crowding at the bridgehead positions. Handling always calls for gloves and goggles, because even trace dust signals its strong physiological effects. Storage for any pharma grade lot keeps the ambient temperature below 25°C, away from acids and oxidizers commonly found in chemical stockrooms.
Every certified package includes full details: percentage purity (reliably above 99.5% for APIs), moisture content via Karl Fischer titration, GC-MS chromatograms for main product and impurity profile, IR and NMR identification, qualified batch numbers that link back to every single raw material and intermediate. Safety labels call special attention to acute toxicity, risk phrases, and emergency spill handling. As soon as a lot lands, incoming inspection teams—usually working for generic manufacturers or academic labs—run quick checks for coloration and clarity before diving into the formal identity tests. The best suppliers even include spectral reference files to let purchasers confirm without question that what’s in the drum fits what’s on the label.
Building 6,6-Dimethyl-3-Azabicyclo[3.1.0]Hexane means controlling ring closure reactions, often relying on cyclopropanation or Mannich-type approaches. Labs start from amino alcohols or pre-formed cyclopropane rings, clip in methyl groups with secure alkylation steps, always watching temperature and base strength to dial back byproduct formation. Industrial routes favor fewer steps, minimal solvent swaps, and pressureless systems where possible. Afterward, vacuum distillation or column chromatography sorts out the product. The entire process spins on controlling exothermic periods and trapping evolved amines, which means you’ll find water scrubbers and organic traps lining the routes from flask to flare. A solid team watches not just for endpoint completion by TLC or GC, but for color and viscosity clues that often show up sooner.
Despite its rigid ring, this molecule opens itself to a range of functionalizations. Selective N-alkylations transform it into quaternary ammonium salts, often used to probe receptor selectivity or solubility behavior in early pharmacology screens. The bicyclic backbone stares down many oxidizers, but controlled hydrogenation or acid hydrolysis can tweak ring electronics for downstream synthesis. Radiolabelers sometimes introduce carbon-13 or deuterium at the methyl positions for tracing metabolic fate in vivo. Cross-coupling reactions don’t favor this core, but acyl agents and mild silylation have let chemists tack groups onto the amine and turn the compound into prodrugs or molecular probes for diagnostic kits. Most of these shifts reflect what research teams see in the earliest animal trial feedback—iterating fast takes on new meaning here.
Depending on the country or supplier, you spot this molecule named as Hexahydro-6,6-dimethyl-3H-azabicyclo[3.1.0]hexane, or sometimes as 6,6-Dimethylbicyclo[3.1.0]hexan-3-amine. Synonyms show up in old patents: 3-Azabicyclohexane, Dimethyltropane, or just Dimethyl-bicyclic amine if a manufacturer wants to dodge chemical registry services. Any reputable outfit lists CAS and EINECS numbers front and center—without this, buyers turn right around. Generics use trade names sparingly, as most applications happen behind closed NDA doors or under research-use labels.
No one treats this compound lightly. Pharma and fine chemical plants keep PPE protocols front and center—face shields, thick gloves, chemical splash aprons. Safety data sheets spell out LD50 numbers, proper spill neutralization protocols, and long-term storage conditions. Fume hoods run at full draw during transfers, and pressure-rated ampules or drums minimize vapor seeping into storage rooms. Fire risks stay low thanks to high flash points, but contact with oxidizers remains off-limits because thermal runaways don’t offer a second chance. Regulatory frameworks in Europe, North America, and parts of Asia demand full chain-of-custody logs and batch records covering at least two years back. Training isn’t a rubber-stamped process—it’s hands-on, demonstration-based, and in audited facilities.
This molecule shows up at the table in more places than most would guess. CNS researchers probe its interactions for new antipsychotic and analgesic leads, as its structure mimics the shape of known neurotransmitter ligands. Some companies harness it as a chiral intermediate—a sort of backbone for building analogues in complex natural product synthesis. In diagnostic chemistry, you find it labeled or derivatized for molecular probes that help map receptor locations in brain tissues. Regulatory paths mean the product can end up as an API precursor or as a reference compound for forensic labs trying to match confiscated designer drugs. Contract research teams favor it for versatility but keep everything documented, as the structural quirks sometimes cause animal model surprises.
Research teams constantly hunt for new angles with this molecule, not just because it checks the box for novel ring systems but due to its action on neuronal pathways. Medicinal chemists test analogues in animal models, mapping behavioral changes tied to bridgehead substitution patterns or ring expansions. Analytical chemists design more sensitive LC-MS/MS methods to pick apart minor metabolite trails, enhancing what pharmacokinetic modelers know about half-life and tissue uptake. Some biotech startups use combinatorial methods, feeding libraries of related compounds against cell-based assays to spot unexpected signal transductions. The literature, especially coming out of neuroscience and pain institutes, brims with structure-activity relationships tied to slight modifications on this skeleton. Investment flows toward both small-molecule drug development and advanced imaging agents based on detailed performance data from these early trials.
Toxicologists treat this structure with the caution typically reserved for synthetic alkaloids. Acute exposure studies using lab rodents pin down no-effect levels and signs of neurotoxicity or liver stress within days. Chronic administration reveals subtle effects in neurotransmitter concentration and receptor downregulation, guiding what doses regulators consider acceptably safe for human study. The ring structure resists rapid metabolic breakdown, causing some prolonged clearance times in controlled trials. Environmental health specialists look for traces in water and waste streams, knowing the molecule’s persistence means cleanup plans take on added urgency. Data from in vitro mutagenicity tests and in vivo carcinogenicity panels guide downstream applications—anything flagged as a potential hazard won’t move past preclinical review in regulated markets. Open access journals often publish both negative and positive results, speeding up community awareness and safety cataloging.
Looking to where this molecule goes over the next decade, the prospects tie directly to ongoing needs in CNS and pain therapeutics. Drug developers bet on its framework as they push for next-generation treatments with lower abuse potential, building off lessons learned from earlier analogues. Big data and AI-assisted screening bring more structure-activity predictions, letting chemists home in on promising candidates with fewer wasted cycles. Regulatory agencies, tightening standards around impurity control and batch reproducibility, push suppliers to automate every step from synthesis to packaging. Sustainability edges forward, with researchers working out bio-catalytic processes to trim waste and cut reliance on hazardous solvents. As diagnostic imaging technologies grow, radiolabeled variants of this core could deliver sharper, earlier detection for neurodegenerative disorders. Competition will run tight, but the companies investing in both product safety and environmental responsibility stand to lead in both compliance and performance.
One glance at the name, 6,6-Dimethyl-3-azabicyclo[3.1.0]hexane, and it sounds like a handful. The chemical structure gives a better story. This compound stands on a bicyclic system—meaning two rings share a pair of carbon atoms. The methyl groups on the sixth position add bulk and influence how this molecule interacts with others. The azabicyclo part hints at nitrogen cycle-jumping into the frame, replacing one of the carbons. The resulting structure carries the molecular formula C8H15N and draws medicinal chemists because rigid cycles often mean unique biological activity.
Numbers can feel dry, but the CAS number for 6,6-Dimethyl-3-azabicyclo[3.1.0]hexane is 62068-68-2. This number links global databases and ensures researchers work on the same page. I’ve often found that matching the exact structure can mean the difference between good science and wasted time. Chemical Abstracts Service records show the utility of this identifier for mapping not just the compound, but all its journeys through research, regulation, and application.
In medicinal chemistry, molecular shape is not just trivia. Structures like 6,6-Dimethyl-3-azabicyclo[3.1.0]hexane give important clues to its reactivity and potential use. Bicyclic systems resist metabolic breakdown, sometimes leading to longer-acting pharmaceuticals. Nitrogen embedded within a cycle often hints at central nervous system activity. Over the years, I’ve seen scaffolds like this attract pharmaceutical startups searching for novel antibiotics, antivirals, or CNS-acting compounds. It’s not always about finding the next big drug. Sometimes, small changes on a structure like this set off a chain of discoveries, from lab bench to clinical testing.
Chemists tend to keep safety sheets close by. Compounds built with strained rings occasionally provoke surprise reactions. Experience teaches me that handling any bicyclic amine requires basic precautions: gloves, proper ventilation, and label everything. Databases and resources from bodies like the U.S. National Library of Medicine help researchers understand toxicological profiles before they venture into synthesis. Regulation moves fast and knowing the exact identity gives a research team confidence, especially in tightly controlled spaces like drug design.
Translating a molecule’s structure into real-world solutions means building reliable supplier networks and enforcing documentation. It helps avoid mishaps over purity, misidentification, or regulatory red tape. Digital registries and tighter lab controls push the field toward best practices, matching the lessons I learned double-checking every bottle on a shelf. Open collaboration, plus wider education on reading chemical structure, narrows the knowledge gap for young chemists. Sharing structural details and safe-handling tips lifts the standards across labs, so breakthroughs come easier—and safer.
This compound, 6,6-Dimethyl-3-Azabicyclo[3.1.0]hexane, turns up when scientists want a building block that brings both stability and reactivity to new medicines. A molecule shaped like this doesn’t show up everywhere—its bicyclic structure creates a strong backbone, letting chemists anchor other pieces where traditional scaffolds can’t reach. There’s real power in versatility, especially as researchers chase treatments that work on tough targets in the brain or immune system.
In my time working alongside teams exploring neuroactive drugs, I’ve seen how a ring system like this plays a huge role. Think about medicines that nudge neurotransmitters, like those prescribed for depression or ADHD. The molecular skeleton at the core needs to fit tightly into the target pocket, or it just won’t work. 6,6-Dimethyl-3-Azabicyclo[3.1.0]hexane provides rigidity, so the rest of the molecule lines up just where it should on the receptor. Medicinal chemists love this precision because it can lead to medicines with fewer off-target effects and side effects. Medications for attention disorders or movement diseases might both start their journey here.
With antimicrobial resistance on the rise, finding structures bacteria haven’t seen before is key. Beta-lactam antibiotics, for example, lost some bite because bacteria evolved. The unique three-dimensional shape of 6,6-dimethyl-3-azabicyclo[3.1.0]hexane opens new paths for antibiotic development, offering a scaffold that enzymes in bacteria may not easily break down. This isn't just chemistry: it’s a direct path to new options for patients running out of alternatives.
Folks in industry care about what goes into their pills, no doubt about it. BP, EP, and USP grades mean strict oversight from raw materials to final use. This level of scrutiny keeps pharmacological research and commercial drug manufacturing safe and predictable. Regulatory standards don't just exist on paper—they shape every batch, so no one faces surprises that can derail clinical trials or, worse, put patient safety at risk. I’ve watched teams reject promising leads simply because a small impurity showed up. That’s the value of pharma grade: it keeps progress on track.
Innovation comes fastest in supportive environments. Academic and commercial labs need reliable sources of chemicals that not only meet tough standards but also arrive with full documentation. The trustworthiness of a supplier makes life easier for everyone—from the grad student pipetting in a university lab to the QA inspector at a pharmaceutical plant. When these expectations get met, failure becomes a learning opportunity, not a disaster. With new mental health challenges, infectious threats, and a greater call for accessible medicine, 6,6-dimethyl-3-azabicyclo[3.1.0]hexane’s chemistry stands as a key tool among those who want more than incremental advances.
In the real world, supply chain hiccups, cost, or changing regulations can all block progress—no molecule changes that reality. Companies and academic groups working closer, sharing data and standards, often get more medicines to market safely. Investment in advanced synthesis, transparent distribution, and ongoing regulatory alignment keeps the spotlight on patient safety and research integrity. That’s how small molecules with big ambitions make their mark.
Quality standards don’t often grab headlines, but anyone taking medicine or working in a pharmacy benefits from them every day. The British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) set the rules for what goes into tablets, capsules, and just about every prescription drug at the pharmacy. Each one covers how pure a drug must be, what counts as a contaminant, and the exact physical and chemical properties it should have. It’s about safety, trust, and making sure anyone opening a bottle knows exactly what’s inside.
Pharmacopoeias demand strict identity tests. If a bottle claims to contain paracetamol, the tests confirm that no other substance can sneak through under that name. The BP and EP both use infrared spectroscopy, melting point checks, or sometimes chromatography. USP pushes for same standards but tailored for drug forms seen in the United States. No leeway here—getting identity wrong can turn medicine harmful, or just useless. A friend working in lab quality control shared horror stories of generics caught using the wrong salt form before a batch left the plant. Those tight rules stopped that mistake from ending up on a pharmacy shelf.
Every batch faces a test of strength. Too much or too little active ingredient means the drug either won’t work or may hurt someone. BP, EP, and USP each set numeric ranges—think 98% to 102% of the label claim. My old chemistry professor used to hammer this home: “Dose accuracy means someone gets better or keeps getting sick.” For most prescription meds, there’s no room for guesswork. Analytical methods include chemical titration or HPLC, giving clear, reproducible results anyone can check.
A small contaminant missed during production might not seem important, but for cancer drugs or IV solutions, even a trace matters. All three pharmacopoeias limit allowable impurities—organic leftovers, solvents, or heavy metals. BP and EP look for these with modern chromatography and mass spectrometry. USP includes limits for elemental impurities like lead and arsenic, reflecting concern in the U.S. about toxic traces. A batch that fails these checks is destroyed, and rightly so.
Tablets need to dissolve at the right rate—too fast or too slow, and problems crop up. The standards spell out disintegration times, moisture limits, and appearance. I once visited a plant where humidity caused a batch to crumble during shipping. The pharmacopoeial rules flagged that long before anything left the building, saving the company reputation and stopping wasted medication. Visual inspection and careful measurement matter in practice, not just on paper.
Many countries rely on more than one set of standards, creating confusion, duplication, or even trade delays. Harmonization makes sense, cutting red tape and bringing safer products to more people. Efforts from organizations like the ICH help push toward common ground. Public transparency around which specification is used on a product label would also boost confidence. In my view, open data and regular inspections protect patients more than endless bureaucracy. Quality isn’t glamorous, but it saves lives every day.
6,6-Dimethyl-3-Azabicyclo[3.1.0]Hexane plays a role in pharmaceutical labs, but its specialized nature doesn’t mean the basics go out the window. I remember walking into a lab years ago, standing in front of rows of chemical bottles—never forgetting the clear message: treat every compound with respect, no matter how familiar it may seem. This compound deserves that same respect, both for personal safety and for the reliability of your results.
Foundations matter. Dry, well-ventilated rooms always top my list for storing pharma-grade chemicals. Moisture sneaks into containers and wrecks more than just a batch—it can alter molecular structure or trigger unwanted reactions. Temperatures should hover in a controlled space, usually between 2°C and 8°C, but never let the temperature slip below freezing. I’ve seen careless temp spikes turn clear, pure liquids into cloudy, inconsistent mixtures.
Light works faster than you think. Some pharmaceuticals break down fast if they get exposed to sunlight or harsh fluorescent lighting. Amber glass bottles or opaque containers give an extra layer of protection, blocking rays that could degrade the material. From personal experience, labeling storage dates on containers makes tracking shelf life a routine, not a headache.
Protective gear always sits at center stage. Gloves—nitrile, not latex—act as the first barrier, since some pharmaceutical intermediates slip through cheaper materials. I’ve had enough stray drops on skin during hurried weigh-outs to know even the small steps mean big safety later. Lab coats and face shields become standard kit, not just for splash protection but for mental readiness, too.
Decent ventilation in storage or working areas isn’t just a recommendation—it saves you from inhaling vapors you might never notice until they start to accumulate. Fume hoods and extraction fans stop hazardous fumes from settling in workspaces. Regular checks of HVAC systems flag any hitches before they start to affect your air quality.
Sealed containers with tight-fitting lids cut down on accidental spills or vapor escapes. Every time I handled similar materials, double-checking seals became second nature. Storing high up, out of the reach of casual passersby or untrained personnel, trims the risk of careless access. I learned early to keep incompatible chemicals far apart. Some substances react if they so much as touch; a mix-up turns a routine day into a scramble for the eyewash station.
Sorbent pads and spill kits sit on-hand, not locked away. Quick action means isolating a spill before it spreads. Used chemicals or contaminated materials never go down the drain. Dedicated waste containers handle all cleanup, heading for certified chemical processing after the workday ends.
Nobody gets by on guesswork. Safety data sheets must be more than paperwork—they become second skin for anyone handling pharma-grade chemicals. I’ve seen teams build short, effective workshops around new materials to brief everyone. Training covers hazards, first aid, and cleanup, not just “what not to touch.” This habit builds a stronger, safer workplace.
At the end of the day, it’s about balancing precision in storage and respect in handling. Mistakes rarely forgive. Storing and working with 6,6-Dimethyl-3-Azabicyclo[3.1.0]Hexane safely means patience, training, and a refusal to cut corners.
Anyone who's ever worked in a lab, manufacturing plant, or food production knows that documentation tells you a lot. A Certificate of Analysis (CoA) and a Material Safety Data Sheet (MSDS) deliver proof and protection in a world where quality and safety aren’t just buzzwords—they keep people healthy and businesses open.
After years spent sweating the details in both quality control and sourcing roles, I’ve run into too many suppliers happy to promise the moon without hard evidence. There's a fine line between trusting a vendor and putting your name on a shipment of raw materials with uncertain origins.
A CoA isn’t just a slip of paper. It gives testing results from real batches, showing the product lives up to what the label claims. If that means verifying the concentration of vitamin C in a supplement powder or confirming the purity of a chemical used for water treatment, the CoA steps up and puts those specifics on record. When a batch changes or a new source gets added, comparing CoAs can spot differences fast, before anything heads out the door.
The MSDS lays out the dos and don’ts when handling products. Ask anyone who’s opened a drum of peroxide or moved a bag of industrial acid—knowing what to expect saves skin, eyes, and sometimes lives. The federal government and OSHA don’t give you leeway here. They want employees and customers covered regarding fire danger, exposure, or storage snafus.
Many shops keep MSDS binders near the phone or entrance. I once stumbled on an unlabelled container in a production bay. Without the MSDS in hand, one spill could have turned into a real emergency. With it, our crew handled cleanup safely and no one missed a shift.
Some folks shrug off paperwork as hassle or bureaucracy. Yet, every documented test result stops mystery ingredients from ending up in food, cosmetics, or electronics. Genuine CoAs build trust with buyers—especially international clients who want proof before sending payment overseas. It’s about food recalls prevented, products cleared at customs, and customers who know what they’re getting.
If you ever doubt the importance, look to recent recalls. Listeria in salad mixes or metal in breakfast bars, with CoA data producers can pinpoint which lot slipped through, cutting risk and cost.
Sometimes small suppliers or companies from regions with different standards balk at providing these documents. Asking for CoAs and MSDS up front weeds out businesses that aren’t prepared to play by the rules. Buyers who demand and review this information shield their operations, employees, and end users from harm.
Training team members to read certificates and sheets shouldn’t fall to the bottom of the to-do list. A basics course or quick huddle around a new product can save headaches—or lawsuits—later.
At trade shows and in customer meetings, seeing suppliers display clear and current certificates sends a signal. They’re ready to invest in safety, traceability, and open communication. Reputable producers already set aside time to prepare and update these documents. Anyone else raises red flags and doesn’t deserve your purchase order.
If companies make promises but can’t back them up with documentation, trust evaporates fast. The process isn’t just for the regulators—it’s for every worker, manager, and customer who puts their name alongside a brand. In a crowded market, clear paperwork still sets the real professionals apart.
| Identifiers | |
| UN number | UN1993 |
Chengguan District, Lanzhou, Gansu, China
